Keele, UK, 23 April 2020 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announced that its STIMULAN products have gained a new European CE mark approval for mixing with antibiotics: vancomycin, gentamicin and tobramycin, for use in infected bone and soft tissue.

STIMULAN® targets high concentrations of antibiotic at the point of infection at levels unachievable systemically – which lowers rates of reinfection, saves costs and improves patient outcomes. The STIMULAN® Rapid Cure and STIMULAN® Kit products are the first and only calcium matrices that can carry an antibiotic into bone and soft tissue; offering surgeons the flexibility to apply a broad spectrum of ‘off-the-shelf’ antibiotics at concentrations that will support their patient-specific treatment plans.

Mr Rhidian Morgan-Jones, Consultant Orthopaedic Surgeon, said: “STIMULAN® is the only product that allows me to place the appropriate antibiotics in bone and soft tissue when treating very challenging infected cases. It has played a key role in transforming the outcomes of some very difficult cases.”

 Michael Harris, Chief Executive Officer of Biocomposites, said: “Our goal is to develop and provide products that can significantly improve patient outcomes and decrease hospital readmissions. This is a breakthrough solution for surgeons managing infection, offering them the flexibility to use their chosen antibiotics at patient-specific concentration levels in both bone and soft tissue.”

STIMULAN® is already used in over 50,000 cases every year and in thousands of hospitals around the world.